WENDY L YARNO
CIK 1181186 · Chief Marketing Officer · last filed 2026-06-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.76M
Companies
12
Total Filings
106
Lifetime Open-Market Net
-$11.91M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TARS | Director | 16,654 | $58.95 | $981.8K | $0 | 12 | 2026-06-29 |
| IDYA | Director | — | $36.16 | — | $0 | 8 | 2026-06-18 |
| INO | Director | 10,512 | $1.03 | $10.8K | $0 | 16 | 2026-05-21 |
| IOVA | Director | — | $4.70 | — | $0 | 5 | 2025-06-17 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | Director | 0 | $68.49 | $0 | $0 | 7 | 2022-10-06 |
| MyoKardia, Inc. (MYOK) Delisted | Director | 3,708 | — | — | $50.0K | 8 | 2020-06-23 |
| ARATANA THERAPEUTICS, INC. (PETX) Delisted | Director | 0 | — | — | $0 | 7 | 2019-07-18 |
| ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Director | 5,000 | — | — | $50.0K | 5 | 2019-05-28 |
| MEDIVATION, INC. (MDVN) Delisted | Director | 32,742 | — | — | $0 | 5 | 2016-06-23 |
| ST JUDE MEDICAL, LLC (STJ) Delisted | Director | 30,240 | — | — | -$1.48M | 19 | 2016-06-03 |
| Durata Therapeutics, Inc. (DRTX) Delisted | Director | — | — | — | $0 | 2 | 2014-11-18 |
| MRK | Chief Marketing Officer | 36,144 | $131.82 | $4.76M | -$10.52M | 8 | 2008-03-04 |
Recent Filings · Page 2 of 11
106 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-13 | IOVA | Grant (A) | — | $0 | EDGAR |
| 2024-05-31 | IDYA | Grant (A) | — | $0 | EDGAR |
| 2024-05-22 | INO | Grant (A) | — | $0 | EDGAR |
| 2024-05-16 | INO | Exer (M) | +2,166 | $0 | EDGAR |
| 2024-03-05 | IOVA | Grant (A) | — | $0 | EDGAR |
| 2023-12-05 | TARS | Exer (M) | +5,000 | $0 | EDGAR |
| 2023-06-26 | TARS | Grant (A) | — | $0 | EDGAR |
| 2023-06-21 | TARS | Exer (M) | +2,000 | $0 | EDGAR |
| 2023-06-09 | IDYA | Grant (A) | — | $0 | EDGAR |
| 2023-06-08 | IOVA | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.